'Less than 2 pc affected by COVID, 98 pc still vulnerable', says govt; approves Covaxin for trials in children

'Less than 2 pc affected by COVID, 98 pc still vulnerable', says govt; approves Covaxin for trials in children

Jagran English

New Delhi | Jagran News Desk: The Union Health Ministry on Tuesday said that the Drugs Controller General of India (DCGI) has approved Bharat Biotech's COVID-19 vaccine, Covaxin, to conduct phase 2 and phase 3 human clinical trials in children aged between 2 to 18 years. As per the health ministry, the trials will start in the next 10-12 days on 525 healthy volunteers from across the country at various testing sites including AIIMS Delhi, AIIMS Patna and Meditrina Institute of Medical Sciences located in Maharashtra's Nagpur.

Addressing a press briefing on COVID-19, Dr VK Paul, Member-Health, Niti Aayog, said, "COVAXIN has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years.


Read all the latest updates on COVID-19 here.
Disclaimer: This is an automatically aggregated article/story by a computer program and has not been created or edited by Newsdig.in.

World COVID19 Meter

177355851

Cases

160208187

Recovered

3838022

Deaths
Last updated: GMT
Advt
Advt
Advt
sitemap Disclaimer
Newsdig.in 2019